Mankind Pharma Limited
MANKIND
Rank in Stocks
#2064
Mankind Pharma Limited specializes in the development, manufacturing, and... Mankind Pharma Limited specializes in the development, manufacturing, and marketing of a broad range of pharmaceutical medications and consumer health goods. Operating predominantly in India, the company also caters to international markets. Its pharmaceutical division focuses on both acute and chronic therapeutic areas, encompassing a wide spectrum of medical conditions such as infectious diseases, cardiovascular ailments, gastrointestinal disorders, diabetes, dermatology, pain management, neuro/CNS issues, nutritional support (vitamins/minerals), and respiratory problems. Complementing its pharmaceutical portfolio, the consumer healthcare segment offers diverse products, including condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. Key brands under its umbrella include Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar. Furthermore, the company's business activities are diversified, extending to the trading and export of pharmaceutical and healthcare products, as well as the manufacturing of various goods such as packaging materials, ayurvedic products, bulk drugs, and general consumer items. Mankind Pharma also holds interests in real estate, leasing, hospitality, and IT services. Established in 1986, Mankind Pharma Limited maintains its headquarters in New Delhi, India.
Share Price
$24.08
Market Cap
$9.95B
Change (1 day)
-4.09%
Change (1 year)
-13.33%
Country
IN
Trade Mankind Pharma Limited (MANKIND)
Category
Healthcare
P/E ratio for Mankind Pharma Limited (MANKIND)
P/E ratio as of October 2026 TTM: 45.98
According to Mankind Pharma Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 45.98. At the end of 2025 the company had a P/E ratio of 49.99.
P/E ratio history for Mankind Pharma Limited from 2019 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 45.98 | -8.02% |
| 2025 | 49.99 | 3.26% |
| 2024 | 48.41 | 8.92% |
| 2023 | 44.45 | 11.83% |
| 2022 | 39.75 | -11.72% |
| 2021 | 45.02 | -18.57% |
| 2020 | 55.29 | -43.86% |
| 2019 | 98.48 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 23.30 | -49.33% |
DE
|
|
| 26.92 | -41.46% |
DE
|
|
| 55.58 | 20.87% |
JP
|
|
| 61.13 | 32.95% |
CH
|
|
| 34.96 | -23.97% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.